VivoSeq
Other

Growth

273

Pipeline Programs↗

42

Active Trials↗

93

Companies Involved↗

Growth is a highly competitive landscape with 273 programs across 93 companies. The most active players are BeOne Medicines, Eli Lilly, IGF Oncology, LLC. 36 therapies are approved with 48 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

85/100

Pipeline Velocity

34/100

Mech. Concentration

6/100

Completion Rate

82/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

B

BeOne Medicines

2 programs

Phase 1Eli Lilly logo

Eli Lilly

1 program

Phase 1I

IGF Oncology, LLC

1 program

Phase 1A

ADC Therapeutics S.A.

1 program

Phase 1N

Nalo Therapeutics Inc.

1 program

Phase 1A

Acepodia Biotech, Inc.

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical58

Trastuzumab

Organon and Co

Lenvatinib

Eisai

Mecasermin Rinfabate

Novo Nordisk

Somapacitan

Novo Nordisk

Metformin

EMD Serono

Phase 159

Pembrolizumab

Merck & Co.

Carboplatin

Avyxa

Pemetrexed

Eagle Vision Pharmaceutical Corp.

Itraconazole

Sebela Pharmaceuticals Development LLC

Paclitaxel

Teva

Phase 272

Sirolimus

Prism Pharmaceuticals

Icotinib

Betta Pharmaceuticals Co., Ltd.

Amoxicillin-Clavulanate

Iterum Therapeutics, International Limited

Erlotinib

Dutch Society of Physicians for Pulmonology and Tuberculosis

Everolimus

Novartis

Phase 348

Erdafitinib

Johnson & Johnson

Platelet Rich Plasma

Zagazig University

Vinflunine

Bristol-Myers Squibb

Capecitabine

Engelhard Arzneimittel GmbH & Co.KG

Docetaxel

Avyxa

Approved36

Exendin-(9-39)

Eiger BioPharmaceuticals

Risperidone

Wim Janssens

Anastrozole

Istituto Clinico Humanitas

Calcium Carbonate

Otsuka

Ciprofloxacin

Bayer

Analysis

Modality Breakdown

91%

Small molecule

311 of 340 classified programs — the dominant modality here.

9%ALL OTHERSProtein / enzyme134%Monoclonal antibody103%Cell therapy3<1%Peptide2<1%Vaccine1<1%

Small molecule leads; the ring shows all 340 classified programs, each share of the total. Modality classified for 99% of 365 pipeline programs.

Analysis

Trial Status

410

clinical trials

Completed249 · 61%
Unknown status59 · 14%
Terminated45 · 11%
Recruiting20 · 5%
Active, not recruiting12 · 3%
Withdrawn10 · 2%
Other15 · 4%

Clinical Trials

Trial Activity

410 trials

The MOM-CARE Trial : Evaluating Antenatal and Postnatal MMSPlus for Improved Infant Birth and Growth Outcomes
Recruiting·—·Phase 3·NCT07029282·3,000 enrolled
Donation of Whole Blood by Healthy Volunteers After Mobilisation by Haematopoietic Growth Factor (Rhu-G-CSF = Granocyte)
Recruiting·CCellProthera·Phase 1·NCT05594433·40 enrolled
The Application of Bovine Basic Fibroblast Growth Factor Gel in the Treatment of Sensitive Skin
Recruiting·SShanghai Dermatology Hospital·N/A·NCT06516939·28 enrolled
Pilot Feasibility Study of Fecal Microbiota Transplant for the Treatment of Small Intestinal Bacterial Overgrowth
Recruiting·MMcMaster Children's Hospital·Phase 1·NCT05967871·20 enrolled
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation
Recruiting·Relay Therapeutics logoRelay Therapeutics·Phase 2·NCT06789913·277 enrolled
Anti-vascular Endothelial Growth Factor (Anti-VEGF) Monotherapy vs Anti-VEGF Followed by Subthreshold Micropulse Laser for Treating Severe Diabetic Macular Oedema When the Central Retina Goes <400 Microns
Recruiting·BBelfast Health and Social Care Trust·Phase 3·NCT06985706·264 enrolled
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Recruiting·EEsteve Pharmaceuticals, S.A.·N/A·NCT00903110·500 enrolled
Efficacy of Rifaximin in Patients With Small Intestinal Bacterial Overgrowth Presenting With Abdominal Bloating.
Recruiting·—·N/A·NCT06772064·115 enrolled
To Study Effect of Injection Pentoxifylline on Liver Growth After Major Liver Surgery
Recruiting·IInstitute of Liver and Biliary Sciences, India·N/A·NCT07085806·60 enrolled
Growth Hormone Replacement Therapy for Retried Professional Football Players
Recruiting·CCenter for Neurological Studies·Phase 2·NCT04121780·42 enrolled
Ridge Augmentation Using Allograft Particles Hydrated With or Without Recombinant Human Platelet-Derived Growth Factor
Recruiting·UUniversity of Alabama at Birmingham·N/A·NCT04954664·44 enrolled
ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)
Recruiting·AAcepodia Biotech, Inc.·Phase 1·NCT06415487·30 enrolled
Plasma Rich in Growth Factors in Corneal Endothelial Transplantation
Recruiting·UUniversity of Miami·N/A·NCT06261346·100 enrolled
Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT)
Recruiting·—·Phase 2·NCT05355272·20 enrolled
Long-term Efficacy and Safety Evaluation of Growth Hormone in Children in China(CGLS)
Recruiting·—·N/A·NCT06110910·10,000 enrolled
Page 1 of 28

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)